We would love to hear your thoughts about our site and services, please take our survey here.
Burble,
Targeting/testing/analyses also seems to lean one particular way that of ctDNA rather than the burgeoning CTC's (which offer DNA, RNA, and protein analyses). Development takes place as it does and it will always be in favour of one than the other. It would take a lot to switch focus. Especially with the long development time lines of drugs so it is difficult to see how one can just switch focus to DNA. Unless, of course big pharma is so interested in Scancell's work and they have no conflicting interest so that switching simply is not an issue? They could be tempted to steel a march. I would be interested to know, do big pharma adopt innovative drug candidates that are not inline with the current way of thinking so easily?
However we have to remember of course that there is an overlap with Scancells work involving checkpoint inhibitors. Many more no doubt too. So it is not too far out afterall?
Yes and the UK labs are operational under the Good Medical Practice scheme. Still need real validation but good to see them being utilised. Everything with P is complex as it begins to penetrate the market which gives TGTD and Co good purchase critically but the only people persuaded by them would be under researched or none researched investors. You do not need good scientific knowledge - either in general or specific terms to eviscerate the derampers arguments , but in doing so publically you end up educating those that cannot be bothered to work things out for themselves. Especially of knowledge garnered from the much valued TeleG group. Hence why I do not engage with them on the whole.
Let them remain in the dark of the one sided echo chamber.
ATB
HI Davey,
Good post. The only other one you missed was when it jumped from 11p to 28p last year! This just underlines your point. With expected news flow it is plausible to suggest that it may move upwards again in an equally significant way?
ATB
In ANY AIM Co it is potential vs reality. That is until potential matches reality too break even, profitability, or not. What you are saying is that this principle is floored. My question is why are you bothered.
TGTD, I will put forward the following facts:
DDR assay developed for Artois for which Angle were paid and now Angle are actively marketing to other customers!
Her2 assay developed for Eisai (Japan) for which Angle will be paid £250k - this is a favourite of derampers 🤡. Who knows, it could lead to a bigger contract?
All I would say is Angle are picking the low hanging fruit and thank goodness they are and not reaching for all cancer validation. That would be nuts 🐿️
Re NGS. Dunno. They have said they have work to do on this and that is the way I read things first time reading the RNS. I was actually surprised that news did so well but it took me a little time to fully appreciate. I am sure you will feel the same way too at some point.
ATB
Really? 24 cancer types? One step at a time...The FDA already told Angle to rethink a whole cancer approach and address each cancer type one at a time. Would cost billions to tackle all cancers!
TGTD,
You talk about financial realities but with a long term view. You do not however acknowledge the potential and May I remind you that this share hit 37p a couple of weeks ago based on potential. Imo your posts lack balance and you in fact require others to make the balance for you. When people do you argue and talk down to people. So basically people ignore you I guess?
What I am wondering is besides the two NGS systems (illumina and Thermo Fisher which have been named dropped recently by AN and IG) are there any other NGS systems that Angle could use or are there any other none NGS platforms that could be used and which would offer particular benefits and limitations. So essentially, what is the thinking that Angle has had to undertake to present the best results. Sorry if that is a massive question. It may well just be one of the lead NGS systems which would be fine wouldn't it.
Mia,
You are right to underline Angles strategy of utilising the installed base of some 3000+ NGS systems. If Parsortix is a seamless fit why not! Also the economy point you make re: Ziplex is spot on thanks.
I also wonder what the benefits or limitations might be of choosing NGS to process these samples. It is clear that after using its own in house molecular system that Angle have to get this right so that the results are beyond dispute